CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lexicon Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lexicon Pharmaceuticals Inc
2445 Technology Forest Blvd, 11Th Floor
Phone: (281) 863-3000p:281 863-3000 THE WOODLANDS, TX  77381  United States Ticker: LXRXLXRX
Business Summary
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 Morningstar DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board RaymondDebbane 69 2/22/2012 8/28/2007
Chief Executive Officer, Director MichaelExton 54 7/8/2024 7/8/2024
Executive Vice President - Innovation and Chemical Sciences Alan J.Main 61 9/1/2020 7/1/2001
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
LEXICON PHARMACEUTICALS 350 Carter Rd Princeton New Jersey United States

Business Names
Business Name
Lexicon Pharmaceuticals (New Jersey), Inc.
LXRX

General Information
Number of Employees: 285 (As of 3/21/2024)
Outstanding Shares: 361,492,295 (As of 9/30/2024)
Shareholders: 313
Stock Exchange: NASD
Federal Tax Id: 760474169
Fax Number: (281) 863-8088
Email Address: jwolford@lexgen.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024